SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 12B-25
COMMISSION FILE NUMBER 0-12183
NOTIFICATION OF LATE FILING
(Check One): XForm 10-K _Form 11-K
_Form 20-F Form 10-Q _Form N-SAR
For Period Ended : December 31,1999
Transition Report on Form 10-K
Transition Report on Form 10-Q
Transition Report on Form 20-F
Transition Report on Form N-SAR
Transition Report on Form 11-K
For the Transition Period Ended:
Read attached instruction sheet before preparing form, please print or type.
Nothing in this form shall be construed to imply that the commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above, identify
the item(s) to which the notification relates:
PART I
REGISTRANT INFORMATION
Full name of registrant BOVIE MEDICAL CORP.
Former name if applicable An-Con Genetics, Inc.
Address of principal executive offices
734 Walt Whitman Road, Suite 207
Melville, NY 11747
PART II
RULE 12-b25: (b) and (c)
If the subject report could not be filed without unreasonable effort or expense
and the registrant seeks relief pursuant to rule 12b-25 (b), the following
should be completed. (check appropriate box).
X(a) The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;
X(b) The subject annual report, semi-annual report, transition report, on Form
10-K, 20-F, 11-K or Form N-SAR, or portion thereof will be filed on or before
the 15th calendar day, following the prescribed due date; or the subject
quarterly report or transition report on Form 10-Q, or portion thereof will be
filed on or before the fifth calendar day following the prescribed due date; and
(c) The accountant's statement or other exhibit required by Rule 12b-25 (c)
has been attached if applicable.
PART III
NARRATIVE
State below in reasonable detail the reasons why Form 10-K, 11-K, 20-F, 10-q,
N-SAR or the transition report portion thereof would not be filed within the
prescribed time period.
Additional time required for the filing of the 10KSB for the Year ended December
31, 1999 due to the time required to prepare certain documents, analyze and
evaluate certain transactions.
PART IV
OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Andrew Makrides
(Name)
516 421-5452
(Telephone)
(2) Have all other periodic reports required under section 13 or 15(d)of the
Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of
1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
XYes No
(3) Is it anticipated that any significant change in results of operations from
the corresponding period for the last fiscal year will be reflected by the
earnings statement to be included in the subject report or portion thereof?
Yes XNo
If so: attach an explanation of the anticipated change, both narratively and
quantitatively, and , if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
BOVIE MEDICAL CORP.
(Name of Registrant as specified
in Charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date 3/28/00
By S/Andrew Makrides
President Instruction. The form may be signed by an executive officer of the
registrant or by any other duly authorized representative. The name and title of
the person signing the form shall by typed or printed beneath the signature. If
the statement is signed on behalf of the registrant by an authorized
representative, (other than an executive officer), evidence shall be filed with
the form of the representative's authority to sign on behalf of the registrant
shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal criminal
violations (see 18 U.S.C. 1001).
GENERAL INSTRUCTIONS
1. This form is required by Rule 12b- 25 of the General Rules and Regulations
under the Securities Exchange Act of 1934.
2. One signed original and four conformed copies of this form and amendments
thereto must be completed and filed with the Securities and Exchange Commission,
Washington, DC 20549, in accordance with Rule 0-3 of the General Rules and
Regulations under the Act. The information contained in or filed with the form
will be made a matter of the public record in the Commission files.
3. A manually signed copy of the form and amendments thereto shall be filed with
each national securities exchange on which any class of securities of the
registrant is registered.
4. Amendments to the notifications must also be filed on Form 12b-25 but need
not restate information that has been correctly furnished. The form shall be
clearly identified as an amended notification.
5. Electronic Filers. This form shall not be used by electronic filers unable to
timely file a report solely due to electronic difficulties. Filers unable to
submit a report within the time period prescribed due to difficulties in
electronic filing should comply with either Rule 201 or Rule 202 of Regulation
S-T or apply for an adjustment in filing date pursuant to Rule 13(b)of
Regulation S-T.
